天美传媒

Dr. Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She completed her internal medicine residency in Rutgers New Jersey Medical School and fellowship at the Mayo Clinic in Rochester, Minnesota where she was the chief fellow from 2018-2019.
Dr. Florez's clinical interests include targeted therapy for lung cancer and the care of women with lung cancer, including their unique aspects of cancer survivorship. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer.
Apart from her clinical interests in lung cancer, she is also a leading and productive researcher in cancer health disparities, gender and racial discrimination in medical education and medicine. She received many awards including the 2018 Resident of the Year Award by the National Hispanic Medical Association, the Mayo Brothers Distinguished Fellowship award and the 2020 Rising Star award by the LEAD national conference for women in hematology and oncology.
In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine and medical education. The laboratory long-term goals are to create a welcoming environment for medical trainees from historically underrepresented groups in medicine while improving the care of vulnerable populations. Members of the Florez Lab are agents of change.

Heinz-Josef Lenz, M.D., FACP, is the Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center. Dr. Lenz is Professor of Medicine and Preventive Medicine, Section Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California.
Dr. Lenz received his medical degree from Johannes-Gutenberg Universität in Mainz, Germany, in 1985. He completed a residency in Hematology and Oncology at the University Hospital Tübingen in Germany, a clerkship in Oncology at George Washington University in Washington, DC, and a clerkship in Hematology at Beth Israel Hospital of Harvard Medical School in Boston, Massachusetts. He served subsequent fellowships in Biochemistry and Molecular Biology at the USC Norris Comprehensive Cancer Center.
An active researcher, Dr. Lenz focuses on topics including the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. He is a member of several professional societies, including the American Association for Cancer Research, the American Gastroenterology Association, and the National Society of Genetic Counselors. He also serves on the National Advisory Board of a number of professional organizations. Dr. Lenz is the author of numerous peer-reviewed publications and invited papers, reviews, and editorials. He also serves as Co-Chair of the GI Committee and Correlative Science Committee for SWOG. He is a member of the NCI Task Force for Gastroesophageal Cancer, the NCI Steering Committee and the NCI Translational Science Committee. In addition to having an NCI-funded laboratory, he was a recipient of the ASCO Young Investigator Award, the ASCO Career Development Award, and the STOP Cancer Career Development Award. He received in 2021 the USC Mentoring Award as well as highly cited researchers in the world. He has been select as influential leader by the LA Business Journal in 2021 and 2023.
As Deputy Cancer Center Director for Research Programs and Co-Director for the Center for Cancer Drug Development, Dr. Lenz oversees the programmatic and clinical activities of the Gastrointestinal Cancers, Genitourinary Cancers, Women’s Cancers, and Leukemia and Lymphoma Programs.

Dr. Jorge Nieva graduated from the University of California, Irvine College of Medicine in 1997, trained in internal medicine at University of California, San Diego and in oncology and hematology at the Scripps Clinic. In 2003 he joined the faculty of the Scripps Research Institute and the medical staff of the Scripps Clinic in La Jolla, CA. While at Scripps, Dr. Nieva pioneered new technology for the detection of cancer cells in the peripheral blood and discoveries related to the fundamental mechanisms of the immune system.
Dr. Nieva was recruited to the Billings Clinic in Montana in 2007 where he served as department chair and was a program leader who established the multidisciplinary lung cancer and head/neck cancer clinics at the cancer center. While in Billings, Dr. Nieva led efforts to establish a research program in virus-delivered cancer gene therapy and immunotherapy. His teams were awarded certificates for excellence in the conduct of cancer clinical trials from the National Cancer Institute and the American Society of Clinical Oncology. Dr. Nieva returned to California, joining the faculty of the Keck School of Medicine in 2014.

Dr. Rachel Freedman is a medical oncologist and clinical researcher at DFCI in the Breast Oncology Program.  In addition to seeing patients with breast cancer, her research focuses on improving the care of vulnerable patient populations who are under-represented in clinical trials and who are at risk for worse breast cancer outcomes, including older women and those who face challenges in access to care.  In addition, she is interested in novel therapeutics, serving as the Principal Investigator for several clinical trials.  She is also the founder and Director of the Program for Older Adults with Breast Cancer at DFCI.  Dr. Freedman joined the faculty at DFCI in 2009.  She studied at Georgetown University School of Medicine and obtained her master's in public health at the Harvard University T.H. Chan School of Public Health.  Her research has been funded by Susan G Komen, ACS, NCI, Gateway for Cancer Research, METAvivor, and the Alliance for Clinical Trials Foundation.

Dr. Garrido-Castro is a medical oncologist specialized in breast cancer at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.  Since joining the Breast Oncology Center at Dana-Farber in 2016, Dr. Garrido-Castro has established an active clinical practice and research efforts focused on the development of novel therapies to improve outcomes in patients with breast cancer.  Dr. Garrido-Castro is Co-Director of the Triple-Negative Breast Cancer (TNBC) Working Group at Dana-Farber and leads clinical trials studying immunotherapy and targeted therapy approaches for patients with breast cancer.

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. 




 

Gilbert Youssef, MD is Neuro-Oncologist at Dana-Farber Cancer Institute.  He primarily treats patients with brain and spinal cord tumors, including, glioma, meningioma, ependymoma, medulloblastoma, schwannoma, lymphoma, and brain metastases.  He also treats patients who develop neurologic complications from cancer or its treatment.
He is interested in neuroimaging, while focusing on clinical endpoints in clinical trials.  He is also involved in multiple clinical trials that are ongoing at Dana-Farber.

Dr. Wen graduated from the Medical College of St. Bartholomew's Hospital, University of London, in 1981. He completed his internal medicine training at the University of London postgraduate hospitals and his neurology residency in the Harvard-Longwood Neurology Training Program. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer.




 

Dr. Kehl received his MD from the Feinberg School of Medicine at Northwestern University in 2008. He completed his residency in internal medicine at the Brigham and Women’s Hospital. He received his fellowship training in hematology and medical oncology at the MD Anderson Cancer Center and joined the faculty in the Lowe Center for Thoracic Oncology and the Division of Population Sciences at Dana-Farber in 2017. His research focuses on the impact of healthcare delivery strategies on access to care and outcomes for patients with lung cancer, with a particular focus on analysis of population-level data.




 

Dr. Manz graduated from Duke University School of Medicine in 2012. He received his training in internal medicine at the Hospital of the University of Pennsylvania from 2012-2015, and subsequently worked as a hospitalist in oncology at the same hospital until 2017. After completing fellowship in hematology/oncology and a Masters of Science in Health Policy Research at the University of Pennsylvania, he joined Dana-Farber in GI Oncology and the Department of Population Sciences 2020.

Dr. Jänne received his MD and PhD from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women's Hospital and in medical oncology at DFCI in 2001. He is the Senior Vice President for Translational Medicine and the Scientific Director of the Belfer Center for Applied Cancer Science. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. He was one of the co-discoverers of epidermal growth factor receptor (EGFR) mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.




 

Dr. Shulman studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas.




 

Church is a board-certified Pediatric Pathologist and Molecular Genetic Pathologist. She is the Associate Director of the Laboratory for Molecular Pediatric Pathology (LaMPP) at Boston Children’s Hospital, and an Assistant Professor at Harvard Medical School.? She has participated in several high-impact studies using molecular profiling for pediatric cancers, including the?iCat?study, Profile study, and the ongoing multi-institutional GAIN consortium study and Broad Institute's Count Me In study.? Her career is dedicated to implementing high-quality accessible molecular profiling tests to support the care of children with cancer.

Dr. Marron received his medical degree from the David Geffen School of Medicine at UCLA in 2008. He completed his residency in Pediatrics at Stanford University and his fellowship in Clinical Medical Ethics at the University of Chicago followed by his fellowship in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute. Dr. Marron also received an MPH in 2016 from the Harvard T.H. Chan School of Public Health. Jonathan cares for pediatric oncology patients in the inpatient setting at Boston Children's Hospital and in the outpatient clinic at the Dana-Farber Cancer Institute. His research interests are in ethics and decision-making, health services, clinical genomics, informed consent, and medical uncertainty. Much of Dr. Marron's current work focuses on patient, parent and physician decision-making regarding pediatric precision cancer medicine. He also teaches medical ethics to medical students and graduate students through his role as teaching faculty at the Harvard Medical School Center for Bioethics.

Dr. Gillani uses computational techniques to understand the markers in cancer and normal patient genomes that are associated with the development and progression of disease, leveraging these insights to inform novel approaches to the treatment of pediatric cancer. He cares for patients with a range of solid tumor and hematologic malignancy diagnoses, with the overall aim of translating research insights to improved patient management.




 

The diagnosis of cancer is incredibly difficult for anyone, but when it’s your child, it’s particularly devastating. I make sure to reassure patients, parents, families and caregivers that this is a partnership and a journey we will weather together. Part of my job is to teach them about the tumor, the treatment, and expected side effects of that treatment, but what they don’t initially realize is how much they will teach me in return. I’ve had years of training to prepare for this; they have had but a few weeks. Yet one of the most rewarding parts of my job is to watch my patients, their families and caregivers transition from students to teachers. I think it’s important to also acknowledge that although we may not cure every patient with a brain tumor, we will help patients to live as long and as well as possible with current therapies and supportive care.




 

Dr Jennifer M. Yeh is a decision scientist whose research focuses on improving health outcomes at the population level. She is an Assistant Professor of Pediatrics at Harvard Medical School and Boston Children’s Hospital. Dr Yeh has an M.S. in Health Policy and Management from the Harvard T.H. Chan School of Public Health and a PhD in Health Policy from Harvard University. She has extensive experience applying decision-analytic modelling and cost-effectiveness analysis methods to evaluate clinical guidelines and inform health policy. Her research identifies opportunities to improve cancer control efforts spanning across the cancer continuum from prevention to survivorship. She is funded by the National Cancer Institute (NCI), the National Institute of Child Health and Human Development (NICHHD), and the American Cancer Society (ACS).

Dr. Erfani graduated from the School of Medicine at the National University of Iran, Tehran, Iran in 2014. He was offered a full scholarship to study MPH in 2013 and graduated from the School of Public Health in 2015. Seyed Hadi is currently a Post-doctoral Research Fellow in the Department of Obstetrics and Gynecology at the Baylor College of Medicine in Houston, Texas, where he is involved in multiple clinical, basic science and epidemiologic research projects related to Obstetrics and Gynecology and Maternal Fetal Medicine.

I am a breast medical oncologist and serve as the Medical Co-Director for Cancer Survivorship and Translational Behavioral Science Program at the Sylvester Comprehensive Cancer Center. I am also the Associate Director of Community Outreach of the Breast Cancer Program at Sylvester-Plantation. Since graduating from a Hematology Oncology Fellowship in 2008, I dedicated my career exclusively to building expertise in breast cancer prevention, treatment, and survivorship. Immediately after my fellowship, I joined Memorial Cancer Institute in Broward County, where I had the privilege to participate in several committees focused on patient satisfaction and quality improvement.

My goal was always to provide outstanding care that not only offers standard treatments but participation in vital clinical trials that offer patients innovative treatments before their approval. I served as a member of the local IRB for 8 years prior to 2015, when I joined University of Miami. Since joining our institution, I was invited to become a PRMC member and a member of Social Behavior committee. I value this committee and their role of making sure best research is available to our patients, not only scientifically but also ethically. I am committed to bringing new trials to our Breast Cancer Program and I am serving as a Principal Investigator on more than 10 clinical trials at the present time. I am the chair-elect for the ASCO lead TAPUR clinical trial and the local PI for TAPUR.

I have worked closely with Dr. Crane and her team on this application entitled, Comparative Effectiveness of Lifestyle Interventions for Older Cancer Survivors and Their Caregivers: the VITALITY Trial and will serve as Co-Investigator for this study. I will serve as a champion for this study for recruitment and provide my clinical oncology expertise in breast cancer to address participant related issues that may arise during this study including determining patient eligibility on a case by case basis, participate in regular research meeting, data interpretation and dissemination of findings.

Coral Olazagasti, MD is an assistant professor at the Sylvester Cancer Center, University of Miami at Miami, Florida. Dr. Olazagasti developed an interest in lung cancer screening while witnessing that the majority of new referrals during an outpatient oncology elective presented with advanced stages of lung cancer. Being a Latina physician, she is personally invested in ethnic and racial disparities in the medical field and has drawn on her own experiences to highlight the inequities and barriers that minority patients face in healthcare. She hopes to continue to expand her research passions and help close the gap for minorities and vulnerable populations.